Nykode Therapeutics ASA Market Cap ($123.19 Million)
Market Cap & Net Worth: Nykode Therapeutics ASA (NYKD)
Nykode Therapeutics ASA market cap. Nykode Therapeutics ASA (OL:NYKD) has a market capitalization of $123.19 Million (Nkr1.17 Billion) as of November 8, 2026. Listed on the OL stock exchange, this Norway-based company holds position #18167 globally and #158 in its home market, demonstrating a -0.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nykode Therapeutics ASA's stock price Nkr2.99 by its total outstanding shares 391546444 (391.55 Million). Also see Nykode Therapeutics ASA cash conversion from operations for how efficiently the company converts equity into cash flow.
Nykode Therapeutics ASA Market Cap History (2020–2026)
Nykode Therapeutics ASA market cap history from 2020 to 2026. Data shows change from $3.09 Billion to $123.19 Million (-38.85% CAGR). Check today's stock price for Nykode Therapeutics ASA for real-time trading data and today's change.
Nykode Therapeutics ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nykode Therapeutics ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Nykode Therapeutics ASA (NYKD) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.46x
Nykode Therapeutics ASA's market cap is 14.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.09 Billion | $215.00 Million | $149.77 Million | 14.37x | 20.63x |
| 2021 | $3.32 Billion | $33.96 Million | -$9.41 Million | 97.90x | N/A |
| 2022 | $1.16 Billion | $7.17 Million | -$42.74 Million | 161.63x | N/A |
| 2023 | $881.72 Million | $12.90 Million | -$35.15 Million | 68.34x | N/A |
| 2024 | $125.50 Million | $8.68 Million | -$38.82 Million | 14.46x | N/A |
Competitor Companies of NYKD by Market Capitalization
Companies near Nykode Therapeutics ASA in the global market cap rankings as of November 8, 2026. Also see Nykode Therapeutics ASA total assets for a full breakdown of the balance sheet.
Key companies related to Nykode Therapeutics ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Nykode Therapeutics ASA (2020–2026)
Market capitalization of Nykode Therapeutics ASA from 2020 to today. Between 2020 and today, Nykode Therapeutics ASA's market cap moved from $3.09 Billion to $ 123.19 Million, with a yearly change of -38.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr123.19 Million | +23.96% |
| 2025 | Nkr99.38 Million | -20.81% |
| 2024 | Nkr125.50 Million | -85.77% |
| 2023 | Nkr881.72 Million | -23.90% |
| 2022 | Nkr1.16 Billion | -65.15% |
| 2021 | Nkr3.32 Billion | +7.61% |
| 2020 | Nkr3.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Nykode Therapeutics ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $123.19 Million USD |
| MoneyControl | $123.19 Million USD |
| MarketWatch | $123.19 Million USD |
| marketcap.company | $123.19 Million USD |
| Reuters | $123.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication… Read more